Abraham Anderson

6.2k total citations · 2 hit papers
43 papers, 3.0k citations indexed

About

Abraham Anderson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Abraham Anderson has authored 43 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Abraham Anderson's work include CAR-T cell therapy research (10 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Abraham Anderson is often cited by papers focused on CAR-T cell therapy research (10 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Abraham Anderson collaborates with scholars based in United States, France and United Kingdom. Abraham Anderson's co-authors include F. Stephen Hodi, Kevin Gorski, Reinhard Dummer, Josep Malvehy, Lisa Chen, Antoni Ribas, Jonathan Cebon, Ari M. Vanderwalde, John M. Kirkwood and Igor Puzanov and has published in prestigious journals such as Cell, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Abraham Anderson

41 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

2017 1.1k citations Antoni Ribas, Reinhard Dummer et al. Cell profile →
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

2024 49 citations Yasutoshi Kuboki, Marwan Fakih et al. Nature Medicine profile →

Peers

Countries citing papers authored by Abraham Anderson

Since Specialization

Citations

This map shows the geographic impact of Abraham Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abraham Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abraham Anderson more than expected).

Fields of papers citing papers by Abraham Anderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abraham Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abraham Anderson. The network helps show where Abraham Anderson may publish in the future.

Co-authorship network of co-authors of Abraham Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of Abraham Anderson. A scholar is included among the top collaborators of Abraham Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abraham Anderson. Abraham Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genome analysis uncovers an inverse correlation between alterations in P21‐activated kinases and patient survival across multiple cancer types 2025 ·Physiological Reports ·Josh N. Vo, L.B. La, Abraham Anderson, (unknown), Payaningal R. Somanath	1
2	Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial breakdown → 2024 ·Nature Medicine ·Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, Rona Yaeger, Toshiki Masuishi, Edward Kim, Christine M. Bestvina, Scott Kopetz, Gerald S. Falchook, Corey J. Langer, John C. Krauss, Sonam Puri, (unknown), Emily Chan, (unknown), Lata Mukundan, Abraham Anderson, Qui Tran, David S. Hong	49
3	Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma 2021 ·Journal for ImmunoTherapy of Cancer ·Josep Malvehy, (unknown), Dirk Schadendorf, Ralf Gutzmer, Jean‐Jacques Grob, Joseph J. Sacco, Kevin Gorski, Abraham Anderson, Cheryl A. Pickett, (unknown), Helen Gogas	48
4	MA14.03 Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib 2021 ·Journal of Thoracic Oncology ·Ferdinandos Skoulidis, Martin Schüler, Jennifer Moriatis Wolf, Fabrice Barlési, Timothy Price, Grace K. Dy, Ramaswamy Govindan, Hossein Borghaei, Gerald S. Falchook, (unknown), Suresh S. Ramalingam, Adrian G. Sacher, Alexander I. Spira, Toshiaki Takahashi, Abraham Anderson, Agnes Ang, Tian Dai, (unknown), (unknown), (unknown)	1
5	Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial 2021 ·Nature Medicine ·Reinhard Dummer, David Gyorki, John Hyngstrom, Adam C. Berger, Robert M. Conry, Lev Demidov, Anjali Sharma, Sheryl Treichel, Hoi-Shen Radcliffe, Kevin Gorski, Abraham Anderson, Emily Chan, Mark B. Faries, Merrick I. Ross	89
6	Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib 2021 ·Lung Cancer ·Joshua Bauml, Bob T. Li, Vamsidhar Velcheti, Ramaswamy Govindan, Alessandra Curioni‐Fontecedro, Christophe Dooms, Toshiaki Takahashi, (unknown), Justin I. Odegaard, Fernando Cruz‐Guilloty, Liming Jin, Ying Zhang, Abraham Anderson, Ferdinandos Skoulidis	47
7	MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor 2021 ·Journal of Thoracic Oncology ·David S. Hong, Yung‐Jue Bang, Fabrice Barlési, Greg Andrew Durm, Gerald S. Falchook, Ramaswamy Govindan, Grace K. Dy, K. Park, John H. Strickler, Timothy F. Burns, (unknown), Agnes Ang, J. Russell Lipford, Gataree Ngarmchamnanrith, Abraham Anderson, B.T. Li	0
8	1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib) 2020 ·Annals of Oncology ·David S. Hong, Y-J. Bang, Fabrice Barlési, Greg Andrew Durm, Gerald S. Falchook, Ramaswamy Govindan, Grace K. Dy, K. Park, John H. Strickler, Timothy F. Burns, (unknown), Agnes Ang, J. Russell Lipford, Gataree Ngarmchamnanrith, Abraham Anderson, B.T. Li	6
9	381MO Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib) 2020 ·Annals of Oncology ·David S. Hong, Y-J. Bang, Fabrice Barlési, Greg Andrew Durm, Gerald S. Falchook, (unknown), Grace K. Dy, K. Park, John H. Strickler, Timothy F. Burns, (unknown), Agnes Ang, J. Russell Lipford, Gataree Ngarmchamnanrith, Abraham Anderson, B.T. Li	2
10	A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia 2020 ·International Journal of Hematology ·Keizo Horibe, Joan Morris, Catherine Tuglus, Cédric Dos Santos, James Kalabus, Abraham Anderson, Hiroaki Goto, Chitose Ogawa	9
11	Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) 2019 ·Blood ·Marion Subklewe, Anthony S. Stein, Roland B. Walter, Ravi Bhatia, Andrew H. Wei, David Ritchie, Veit Bücklein, Pankit Vachhani, Tian Dai, Antreas Hindoyan, Suresh Agarwal, Abraham Anderson, Sophia K. Khaldoyanidi, Farhad Ravandi	68
12	Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy breakdown → 2017 ·Cell ·Antoni Ribas, Reinhard Dummer, Igor Puzanov, Ari M. Vanderwalde, Robert H.I. Andtbacka, Olivier Michielin, Anthony J. Olszanski, Josep Malvehy, Jonathan Cebon, Eugenio Fernández, John M. Kirkwood, Thomas F. Gajewski, Lisa Chen, Kevin Gorski, Abraham Anderson, Scott J. Diede, Michael E. Lassman, Jennifer Gansert, F. Stephen Hodi, Georgina V. Long	1142
13	Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study 2014 ·The Lancet Oncology ·Timothy Iveson, Ross C. Donehower, Ірина Давиденко, S. Tjulandin, Andrzej Deptała, Mark Harrison, (unknown), K C Lakshmaiah, Anne Thomas, Yizhou Jiang, Min Zhu, Rui Tang, Abraham Anderson, Sarita Dubey, Kelly S. Oliner, Elwyn Loh	216
14	Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors 2010 ·Clinical Cancer Research ·Michael S. Gordon, Christopher J. Sweeney, David S. Mendelson, S. Gail Eckhardt, Abraham Anderson, Darrin M. Beaupre, Daniel Branstetter, Teresa L. Burgess, Angela Coxon, Hongjie Deng, Paula Kaplan‐Lefko, Ian M. Leitch, Kelly S. Oliner, Lucy Yan, Min Zhu, Lia Gore	133
15	A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma 2010 ·British Journal of Urology ·Patrick Schöffski, Jorge A. García, Walter M. Stadler, Thierry Gil, Eric Jonasch, Scott T. Tagawa, Melanie C. Smitt, Xinqun Yang, Kelly S. Oliner, Abraham Anderson, Min Zhu, Fairooz F. Kabbinavar	58
16	Improved Endpoints for Cancer Immunotherapy Trials 2010 ·JNCI Journal of the National Cancer Institute ·Axel Hoos, Alexander Eggermont, Sylvia Janetzki, F. Stephen Hodi, Ramy Ibrahim, Abraham Anderson, Rachel Humphrey, Brent A. Blumenstein, Lloyd J. Old, J. D. Wolchok	371
17	Pancreatic islet expression profiling in diabetes-prone C57BLKS/J mice reveals transcriptional differences contributed by DBA loci, including Plagl1 and Nnt 2009 ·PubMed ·Abraham Anderson, Joan Helmering, Todd Juan, Chi-Ming Li, (unknown), Melissa Graham, (unknown), Michael A. Damore, Murielle M. Véniant, David J. Lloyd	31
18	Exploratory biomarkers in the HGF/SF:c-Met axis: preclinical and clinical results 2008 ·Cancer Research ·Angela Coxon, Karen Rex, Jan Sun, Jodi Moriguchi, (unknown), Mark Ma, Abraham Anderson, Yun Lan, Michael A. Gordon, Lia Gore, Christopher Sweeney, Lucy Yan, Darrin M. Beaupre, Kelly S. Oliner, Teresa L. Burgess	2
19	VRDD: applying irtual eality visualization to protein ocking and esign 1999 ·Journal of Molecular Graphics and Modelling ·Abraham Anderson, Zhiping Weng	32
20	Structural principles that govern the peptide-binding motifs of class I MHC molecules 1998 ·Journal of Molecular Biology ·Chao Zhang, Abraham Anderson, Charles DeLisi	95

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact